SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: We demonstrated that the genetic deletion of eEF2K in the Scn1a ± mice rescued the main phenotypes such as epileptic seizure and deficit in behavior, which characterized the Dravet syndrome suggesting eEF2K as a possible pharmacological target.